Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.

Cell death & disease - 1 Aug 2024

Li Na, Zuo Ran, He Yuchao, Gong Wenchen, Wang Yu, Chen Liwei, Luo Yi, Zhang Cuicui, Liu Zhiyong, Chen Peng, Guo Hua

Abstract excerpt

Resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a significant cause of treatment failure and cancer recurrence in non-small cell lung cancer (NSCLC). Approximately 30% of patients with EGFR-activating mutations exhibit primary resistance to EGFR-TKIs. However, the potential mechanisms of primary resistance to EGFR-TKIs remain poorly understood. Recent studies have shown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Autophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to MAP Kinase Signaling System

Share to Mice, Inbred BALB C

Share to Mice, Nude

Source

Open in PubMed Open full text

Identifiers

PMID: 39090096
DOI: 10.1038/s41419-024-06945-7
PMCID: PMC11294607

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.PMID 39090096Read ↗

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expressionSemantic proximity Read ↗

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations.Semantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancerSemantic proximity Read ↗

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.Semantic proximity Read ↗

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation.Semantic proximity Read ↗

[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.Semantic proximity Read ↗

Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.Semantic proximity Read ↗

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.Semantic proximity Read ↗

CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 PhosphorylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.